Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Simone Famularo; Matteo Davide DONADON; Federica Cipriani; Davide P Bernasconi; Giuliano LaBarba; Tommaso Dominioni; Maurizio Iaria; Sarah Molfino; Simone Conci; Cecilia Ferrari; Marco Garatti; Antonella Delvecchio; Albert Troci; Stefan Patauner; Silvia Frassani; Maurizio Cosimelli; Giacomo Zanus; Felice Giuliante; Elio Jovine; Maria G Valsecchi; GianLuca Grazi; Adelmo Antonucci; Antonio Frena; Michele Crespi; Riccardo Memeo; Giuseppe Zimmitti; Guido Griseri; Andrea Ruzzenente; Gianluca Baiocchi; Raffaele DallaValle; Marcello Maestri; Giorgio Ercolani; Luca Aldrighetti; Guido Torzilli; Fabrizio Romano; Guido Costa; HE. RC. O. LE. S. Group

doi:10.1016/j.hpb.2020.10.007

Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Simone Famularo, Matteo Davide DONADON, Federica Cipriani, Davide P Bernasconi, Giuliano LaBarba, Tommaso Dominioni, Maurizio Iaria, Sarah Molfino, Simone Conci, Cecilia Ferrari, Marco Garatti, Antonella Delvecchio, Albert Troci, Stefan Patauner, Silvia Frassani, Maurizio Cosimelli, Giacomo Zanus, Felice Giuliante, Elio Jovine, Maria G ValsecchiGianLuca Grazi, Adelmo Antonucci, Antonio Frena, Michele Crespi, Riccardo Memeo, Giuseppe Zimmitti, Guido Griseri, Andrea Ruzzenente, Gianluca Baiocchi, Raffaele DallaValle, Marcello Maestri, Giorgio Ercolani, Luca Aldrighetti, Guido Torzilli, Fabrizio Romano, Guido Costa, HE. RC. O. LE. S. Group

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista

Abstract

Background: Management of recurrence after surgery for hepatocellular carcinoma (rHCC) is still a debate. The aim was to compare the Survival after Recurrence (SAR) of curative (surgery or thermoablation) versus palliative (TACE or Sorafenib) treatments for patients with rHCC.Methods: This is a multicentric Italian study, which collected data between 2007 and 2018 from 16 centers. Selected patients were then divided according to treatment allocation in Curative (CUR) or Palliative (PAL) Group. Inverse Probability Weighting (IPW) was used to weight the groups.Results: 1,560 patients were evaluated, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. Tumor burden and liver function were weighted by IPW, and two pseudo-population were obtained (CUR = 397.5 and PAL = 415.38). SAR rates at 1, 3 and 5 years were respectively 98.3%, 76.7%, 63.8% for CUR and 91.7%, 64.2% and 48.9% for PAL (p = 0.007). Median DFS was 43 months (95%CI = 32-74) for CUR group, while it was 23 months (95%CI = 18-27) for PAL (p = 0.017). Being treated by palliative approach (HR = 1.75; 95%CI = 1.14-2.67; p = 0.01) and having a median size of the recurrent nodule>5 cm (HR = 1.875; 95%CI = 1.22-2.86; p = 0.004) were the only predictors of mortality after recurrence, while time to recurrence was the only protective factor (HR = 0.616; 95%CI = 0.54-0.69; p<0.001).Conclusion: Curative approaches may guarantee long-term survival in case of recurrence.

Lingua originale	Inglese
pagine (da-a)	889-898
Numero di pagine	10
Rivista	HPB
Volume	23
Numero di pubblicazione	6
DOI	https://doi.org/10.1016/j.hpb.2020.10.007
Stato di pubblicazione	Pubblicato - 2021

Accesso al documento

10.1016/j.hpb.2020.10.007

https://hdl.handle.net/11579/199289

Altri file e collegamenti

handle

Cita questo

Famularo, S., DONADON, M. D., Cipriani, F., Bernasconi, D. P., LaBarba, G., Dominioni, T., Iaria, M., Molfino, S., Conci, S., Ferrari, C., Garatti, M., Delvecchio, A., Troci, A., Patauner, S., Frassani, S., Cosimelli, M., Zanus, G., Giuliante, F., Jovine, E., ... Group, HE. RC. O. LE. S. (2021). Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison. HPB, 23(6), 889-898. https://doi.org/10.1016/j.hpb.2020.10.007

@article{4873aad3d9524e8fb65e517880178f6e,

title = "Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison",

abstract = "Background: Management of recurrence after surgery for hepatocellular carcinoma (rHCC) is still a debate. The aim was to compare the Survival after Recurrence (SAR) of curative (surgery or thermoablation) versus palliative (TACE or Sorafenib) treatments for patients with rHCC.Methods: This is a multicentric Italian study, which collected data between 2007 and 2018 from 16 centers. Selected patients were then divided according to treatment allocation in Curative (CUR) or Palliative (PAL) Group. Inverse Probability Weighting (IPW) was used to weight the groups.Results: 1,560 patients were evaluated, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. Tumor burden and liver function were weighted by IPW, and two pseudo-population were obtained (CUR = 397.5 and PAL = 415.38). SAR rates at 1, 3 and 5 years were respectively 98.3%, 76.7%, 63.8% for CUR and 91.7%, 64.2% and 48.9% for PAL (p = 0.007). Median DFS was 43 months (95%CI = 32-74) for CUR group, while it was 23 months (95%CI = 18-27) for PAL (p = 0.017). Being treated by palliative approach (HR = 1.75; 95%CI = 1.14-2.67; p = 0.01) and having a median size of the recurrent nodule>5 cm (HR = 1.875; 95%CI = 1.22-2.86; p = 0.004) were the only predictors of mortality after recurrence, while time to recurrence was the only protective factor (HR = 0.616; 95%CI = 0.54-0.69; p<0.001).Conclusion: Curative approaches may guarantee long-term survival in case of recurrence.",

author = "Simone Famularo and DONADON, {Matteo Davide} and Federica Cipriani and Bernasconi, {Davide P} and Giuliano LaBarba and Tommaso Dominioni and Maurizio Iaria and Sarah Molfino and Simone Conci and Cecilia Ferrari and Marco Garatti and Antonella Delvecchio and Albert Troci and Stefan Patauner and Silvia Frassani and Maurizio Cosimelli and Giacomo Zanus and Felice Giuliante and Elio Jovine and Valsecchi, {Maria G} and GianLuca Grazi and Adelmo Antonucci and Antonio Frena and Michele Crespi and Riccardo Memeo and Giuseppe Zimmitti and Guido Griseri and Andrea Ruzzenente and Gianluca Baiocchi and Raffaele DallaValle and Marcello Maestri and Giorgio Ercolani and Luca Aldrighetti and Guido Torzilli and Fabrizio Romano and Guido Costa and Group, {HE. RC. O. LE. S.}",

year = "2021",

doi = "10.1016/j.hpb.2020.10.007",

language = "English",

volume = "23",

pages = "889--898",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

number = "6",

}

Famularo, S, DONADON, MD, Cipriani, F, Bernasconi, DP, LaBarba, G, Dominioni, T, Iaria, M, Molfino, S, Conci, S, Ferrari, C, Garatti, M, Delvecchio, A, Troci, A, Patauner, S, Frassani, S, Cosimelli, M, Zanus, G, Giuliante, F, Jovine, E, Valsecchi, MG, Grazi, G, Antonucci, A, Frena, A, Crespi, M, Memeo, R, Zimmitti, G, Griseri, G, Ruzzenente, A, Baiocchi, G, DallaValle, R, Maestri, M, Ercolani, G, Aldrighetti, L, Torzilli, G, Romano, F, Costa, G & Group, HERCOLES 2021, 'Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison', HPB, vol. 23, n. 6, pagg. 889-898. https://doi.org/10.1016/j.hpb.2020.10.007

TY - JOUR

T1 - Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

AU - Famularo, Simone

AU - DONADON, Matteo Davide

AU - Cipriani, Federica

AU - Bernasconi, Davide P

AU - LaBarba, Giuliano

AU - Dominioni, Tommaso

AU - Iaria, Maurizio

AU - Molfino, Sarah

AU - Conci, Simone

AU - Ferrari, Cecilia

AU - Garatti, Marco

AU - Delvecchio, Antonella

AU - Troci, Albert

AU - Patauner, Stefan

AU - Frassani, Silvia

AU - Cosimelli, Maurizio

AU - Zanus, Giacomo

AU - Giuliante, Felice

AU - Jovine, Elio

AU - Valsecchi, Maria G

AU - Grazi, GianLuca

AU - Antonucci, Adelmo

AU - Frena, Antonio

AU - Crespi, Michele

AU - Memeo, Riccardo

AU - Zimmitti, Giuseppe

AU - Griseri, Guido

AU - Ruzzenente, Andrea

AU - Baiocchi, Gianluca

AU - DallaValle, Raffaele

AU - Maestri, Marcello

AU - Ercolani, Giorgio

AU - Aldrighetti, Luca

AU - Torzilli, Guido

AU - Romano, Fabrizio

AU - Costa, Guido

AU - Group, HE. RC. O. LE. S.

PY - 2021

Y1 - 2021

N2 - Background: Management of recurrence after surgery for hepatocellular carcinoma (rHCC) is still a debate. The aim was to compare the Survival after Recurrence (SAR) of curative (surgery or thermoablation) versus palliative (TACE or Sorafenib) treatments for patients with rHCC.Methods: This is a multicentric Italian study, which collected data between 2007 and 2018 from 16 centers. Selected patients were then divided according to treatment allocation in Curative (CUR) or Palliative (PAL) Group. Inverse Probability Weighting (IPW) was used to weight the groups.Results: 1,560 patients were evaluated, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. Tumor burden and liver function were weighted by IPW, and two pseudo-population were obtained (CUR = 397.5 and PAL = 415.38). SAR rates at 1, 3 and 5 years were respectively 98.3%, 76.7%, 63.8% for CUR and 91.7%, 64.2% and 48.9% for PAL (p = 0.007). Median DFS was 43 months (95%CI = 32-74) for CUR group, while it was 23 months (95%CI = 18-27) for PAL (p = 0.017). Being treated by palliative approach (HR = 1.75; 95%CI = 1.14-2.67; p = 0.01) and having a median size of the recurrent nodule>5 cm (HR = 1.875; 95%CI = 1.22-2.86; p = 0.004) were the only predictors of mortality after recurrence, while time to recurrence was the only protective factor (HR = 0.616; 95%CI = 0.54-0.69; p<0.001).Conclusion: Curative approaches may guarantee long-term survival in case of recurrence.

AB - Background: Management of recurrence after surgery for hepatocellular carcinoma (rHCC) is still a debate. The aim was to compare the Survival after Recurrence (SAR) of curative (surgery or thermoablation) versus palliative (TACE or Sorafenib) treatments for patients with rHCC.Methods: This is a multicentric Italian study, which collected data between 2007 and 2018 from 16 centers. Selected patients were then divided according to treatment allocation in Curative (CUR) or Palliative (PAL) Group. Inverse Probability Weighting (IPW) was used to weight the groups.Results: 1,560 patients were evaluated, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. Tumor burden and liver function were weighted by IPW, and two pseudo-population were obtained (CUR = 397.5 and PAL = 415.38). SAR rates at 1, 3 and 5 years were respectively 98.3%, 76.7%, 63.8% for CUR and 91.7%, 64.2% and 48.9% for PAL (p = 0.007). Median DFS was 43 months (95%CI = 32-74) for CUR group, while it was 23 months (95%CI = 18-27) for PAL (p = 0.017). Being treated by palliative approach (HR = 1.75; 95%CI = 1.14-2.67; p = 0.01) and having a median size of the recurrent nodule>5 cm (HR = 1.875; 95%CI = 1.22-2.86; p = 0.004) were the only predictors of mortality after recurrence, while time to recurrence was the only protective factor (HR = 0.616; 95%CI = 0.54-0.69; p<0.001).Conclusion: Curative approaches may guarantee long-term survival in case of recurrence.

UR - https://iris.uniupo.it/handle/11579/199289

U2 - 10.1016/j.hpb.2020.10.007

DO - 10.1016/j.hpb.2020.10.007

M3 - Article

SN - 1365-182X

VL - 23

SP - 889

EP - 898

JO - HPB

JF - HPB

IS - 6

ER -

Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo